Evidence map›Paper›PMID 42157845›Full record

ArticleACS medicinal chemistry letters2026

Discovery of 5‑Azaindole Inhibitors of O‑GlcNAcase for the Treatment of Alzheimer's Disease and Related Tauopathies.

Jakob Bouton, Alexis Bretteville, Gary Tresadern, Paul Shaffer, Nigel Austin, Peter Buijnsters, E Peder Cedervall, Nicolas Darville, Ineke Fonteyn, Joseph Leenaerts and 9 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jakob BoutonJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.ORCID https://orcid.org/0000-0003-4193-7644
Alexis BrettevilleJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Gary TresadernJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.ORCID https://orcid.org/0000-0002-4801-1644
Paul ShafferJohnson & Johnson, 1400 McKean Road, Spring House, Pennsylvania 19477, United States.
Nigel AustinJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Peter BuijnstersJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
E Peder CedervallJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Nicolas DarvilleJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Ineke FonteynJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Joseph LeenaertsJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Carolina Martínez LamencaJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Liesbeth MertensJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Daniele PeetersJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Adriana I VelterJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.ORCID https://orcid.org/0009-0009-3238-5623
Yves Van RoosbroeckJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Andreas EbnethJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.
Jose Manuel BartoloméJohnson & Johnson, C/Jarama 75A, 45007 Toledo, Spain.
Andrés A TrabancoJohnson & Johnson, C/Jarama 75A, 45007 Toledo, Spain.ORCID https://orcid.org/0000-0002-4225-758X
Daniel OehlrichJohnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium.ORCID https://orcid.org/0000-0002-3392-1952

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular amyloid-β plaque accumulation and intracellular tau neurofibrillary tangles, with tau pathology correlating more closely with cognitive decline. Modulation of tau phosphorylation through the regulation of O-GlcNAcylation, a post-translational modification controlled by O-GlcNAcase (OGA), represents a promising therapeutic strategy. In this study, we report the optimization of a pyrimidine hit identified by high-throughput screening, leading to the discovery and optimization of a novel series of 5-azaindole-based OGA inhibitors. From this series, compound

Indexed as

5-azaindoleAlzheimer’s diseaseO-GlcNAcase inhibitorsStructure-based designTau pathology

Identifiers

PMID42157845
PMCPMC13181490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.